Enterprise Value

2.257B

Cash

275.8M

Avg Qtr Burn

-34.04M

Short % of Float

21.64%

Insider Ownership

0.52%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IMCIVREE (Setmelanotide) Details
Rare genetic disease, Bardet-Biedl syndrome

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

sNDA

Submission

Setmelanotide Details
Rare genetic disease

NDA

FDA meeting

Phase 3

Data readout

Phase 2

Data readout

Phase 1

Data readout